CLINICAL ANALYSIS OF ASSOCIATION OF CYSTATIN C AND ATRIAL FIBRILLATION
https://doi.org/10.15829/1560-4071-2014-4-ENG-34-38
Abstract
Some studies have disclosed atrial fibrillation (AF) is associated with inflammation. Cystatin C is not only inflammatory markers but also an independent predictor of cardiovascular events.
Aim. We sought to investigate the relationship between serum levels of cystatin C and the occurrence and development of AF.
Material and methods. 134 paroxysmal and persistent AF (AF1 group) and 121 permanent AF (AF2 group) patients in AF group and 154 healthy people in control group were prospectively measured for cystatin C, other inflammatory markers, biochemical indicators, left atrial diameter (LAD), left ventricular diameter (LVD) and left ventricular ejection fraction (LVEF).
Results. (1) Compared with control and AF1 groups, AF2 group had higher values of cystatin C, high sensitivity C reactive protein (hsCRP), LAD and LVD whereas lower values of LVEF (P<0.05). (2) After adjust for age, gender and body mass index (BMI), correlation analysis showed that serum level of cystatin C was closely related to hsCRP, LAD, systolic blood pressure (SBP) and creatinine, the correlation coefficient were respectively 0.658, 0.502, 0.475 and 0.530 (P<0.01), but negatively associated with LVEF (P=0.011) in AF group. (3) Multivariate regression analysis showed the hsCRP, cystatin C, LAD and LVEF entered finally into the regression equation (cystatin C, OR: 3.41, 95%CI: 1.09–11.08, P=0.009).
Conclusion. The serum levels of cystatin C has significant correlation with AF, which indicates cystatin C may play an important role in the process of AF development.
About the Authors
Ping Liu
The Second Hospital of Shandong University, Jinan, Shandong 250033, China
MD, PhD, Department of Cardiology, the Second Hospital of Shandong University, No.247, Beiyuan Road, Jinan, Shandong 250033, P. R. China
Shujian Sui
The Second Hospital of Shandong University, Jinan, Shandong 250033, China
Dongling Xu
The Second Hospital of Shandong University, Jinan, Shandong 250033, China
References
1. Ozaydin M. Atrial fibrillation and inflammation. World J Cardiol. 2010;2 (8): 243–50.
2. Aldhoon B, Melenovský V, Peichl P, et al. New insights into mechanisms of atrial fibrillation. Physiol Res. 2010; 59 (1):1–12.
3. Conen D, Osswald S, Albert CM. Epidemiology of atrial fibrillation. Swiss Med Wkly. 2009; 139 (25–26):346–52.
4. Hagiwara N. Inflammation and atrial fibrillation. Circ J. 2010;74 (2): 246–7.
5. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60 (22):2263–70.
6. Smith JG, Newton-Cheh C, Almgren P, et al.Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol. 2010; 56 (21):1712–9.
7. Lee SH, Park SA, Ko SH, et al. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients. Metabolism. 2010;59 (2):241–6.
8. Hadi HA, Alsheikh-Ali AA, Mahmeed WA, et al. Inflammatory cytokines and atrial fibrillation: current and prospective views. J Inflamm Res. 2010;3:75–97.
9. Battistoni A, Rubattu S, Volpe M. Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol. 2012;157 (2): 160–8.
10. Taglieri N, Fernandez-Berges DJ, Koenig W, et al. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis. 2010;209 (1):300–5.
11. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31 (19):2369–429.
12. Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem. 2009; 55 (11): 1932–43.
13. Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123 (25): 2946–53.
14. McManus DD, Corteville DC, Shlipak MG, et al. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol. 2009;104:1551–5.
15. Soliman EZ, Prineas RJ, Go AS, et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;15 (6):1102–7.
16. Targoński R, Salczyńska D, Sadowski J, et al. Relationship between inflammatory markers and clinical patterns of atrial fibrillation in patients with congestive heart failure. Kardiol Pol. 2008; 66 (7):729–36.
17. Yap YG. Inflammation and atrial fibrillation: cause or para-phenomenon? Europace. 2009;11 (8): 980–1.
18. Conen D, Ridker PM, Everett BM, et al. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J. 2010;31 (14):1730–6.
19. Rienstra M, Sun JX, Magnani JW, et al. White blood cell count and risk of incident atrial fibrillation (from the Framingham Heart Study). Am J Cardiol. 2012;109 (4):533–7.
20. Qing X, Furong W, Yunxia L, et al. Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate. Cardiovasc Diabetol. 2012;11:108.
21. Linssen GC, Rienstra M, Jaarsma T, et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail. 2011;13 (10):1111–20.
Review
For citations:
Liu P., Sui Sh., Xu D. CLINICAL ANALYSIS OF ASSOCIATION OF CYSTATIN C AND ATRIAL FIBRILLATION. Russian Journal of Cardiology. 2014;(4-ENG):34-38. https://doi.org/10.15829/1560-4071-2014-4-ENG-34-38
Views:
568
Email this article 